Synlogic stock.

Synlogic (NASDAQ:SYBX) is another biotech company, this time promising to treat diseases with high unmet need. It is a synthetic biology company focused on harnessing the power of artificial ...Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.Synlogic, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its ...Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are ...CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non …

Ginkgo Bioworks. 11 Aug, 2022, 07:05 ET. SYNB2081 is the second clinical drug candidate developed through the partnership between Ginkgo and Synlogic. CAMBRIDGE, Mass. and BOSTON, Aug. 11, 2022 ...

Oct 20, 2022 · Synlogic was spun out of MIT and uses technology developed by Drs. Tim Lu and Jim Collins. Synlogic was founded in 2014 and became a public company via a reverse merger in 2017. The first ...

١٠‏/٠٦‏/٢٠٢١ ... ... Synlogic's stock price peaked above $50/share. In mid-May, however, the price was just a tenth of that, closing on May 24 at less than $4/share.A. The latest price target for Synlogic ( NASDAQ: SYBX) was reported by Chardan Capital on August 11, 2023. The analyst firm set a price target for $6.00 expecting SYBX to rise …Stock Quote & Chart Analyst Coverage. Corporate Governance. Governance Highlights Leadership Board of Directors Committee Composition Board Diversity Matrix. ... Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study. December …CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the fourth quarter and full year ending December 31, 2022 and provided a business update. “Last year was a tremendous year for …CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the ...

On average, Wall Street analysts predict. that Synlogic's share price could reach $82.50 by Aug 11, 2024. The average Synlogic stock price prediction forecasts a potential upside of 4,025% from the current SYBX share price of $2.00.

Find out all the key statistics for Synlogic, Inc. (SYBX), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.

A. The latest price target for Synlogic ( NASDAQ: SYBX) was reported by Chardan Capital on Friday, August 11, 2023. The analyst firm set a price target for 6.00 expecting SYBX to rise to within 12 ...The Investor Relations website contains information about Synlogic's business for stockholders, potential investors, and financial analysts.Over the past week, Wood has been accumulating shares of Verve Therapeutics (VERV-6.12%) for her firm's flagship growth stock fund, the ARK Innovation ETF (ARKK 0.43%), and the biotech-focused ARK ...May 13, 2023 · Synlogic Revenues and Earnings Beat Expectations. Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) also surpassed analyst estimates by 1.1%. Looking ahead, revenue is forecast ... With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.

CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SYNB1934 for the treatment of phenylketonuria (PKU). “We are …Cash runway expected into H2 2024. CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and ...Ginkgo has purchased 6,340,771 shares of Synlogic common stock as well as pre-funded warrants to purchase up to 2,548,117 shares of Synlogic common stock, both at a price of $9.00 per share. Gross proceeds to Synlogic are approximately $80 million. The transactions were executed and closed on June 11, 2019.CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to ...The Investor Relations website contains information about Synlogic's business for stockholders, potential investors, and financial analysts.Chg %. Market Cap. Molecular Templates Inc. 4.65%. $33.48M. SYBX | Complete Synlogic Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full …Synlogic enacted this reverse stock split to boost the price of its shares and avoid delisting. The company’s stock previously closed out trading at just 28 cents. That’s below the $1 minimum ...

Synlogic ( SYBX) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 9, 2023 for Q3 and the Actual Revenue was $393K, which beat the ...

Synlogic, Inc. (SYBX) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Add to watchlist. 1.9600 -0.1400 (-6.67%) At close: 03:55PM EST. 1d.May 24, 2023 · CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced its planned presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) conference being held May 30 – June 2, 2023 in Los Angeles, CA. Synlogic to Implement 1-for-15 Reverse Stock Split Sep. 28: MT Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000 Aug. 10: MT Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 Aug. 10: CI Science 37's Metasite ...Synlogic, Inc. (SYBX) Stock Price, Quote, News & Analysis Black Friday is here! Save 45% on Premium AND Alpha Picks now » SYBX Synlogic, Inc. Stock Price …Based on short-term price targets offered by three analysts, the average price target for Synlogic, Inc. comes to $21.67. The forecasts range from a low of $6.00 to a high of $35.00. The average ...Synlogic to Implement 1-for-15 Reverse Stock Split Sep. 28: MT Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000 Aug. 10: MT Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 Aug. 10: CI Science 37's Metasite ...Chardan Capital currently has a “Buy” rating and a $90.00 target price on the stock. The consensus estimate for Synlogic’s current full-year earnings is ($6.25) per share. Chardan Capital also issued estimates for Synlogic’s FY2024 earnings at ($3.87) EPS. Separately, HC Wainwright reaffirmed a “buy” rating and set a $75.00 target ...٢٧‏/٠٩‏/٢٠٢٣ ... Synlogic (SYBX) Announces Reverse Stock Split ... Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non ...Synlogic Inc () Stock Market info Recommendations: Buy or sell Synlogic stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Synlogic share forecasts, stock quote and buy / sell signals below.According to present data Synlogic's SYBX shares and potentially its market environment have been in a bullish …

Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...

CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the European ...

Open a brokerage account and deposit funds in it to purchase stock in a company, explains the Wall Street Journal. Companies such as Charles Schwab, E-Trade, and Ameritrade provide brokerage services.Nov 29, 2023 · 2 equities research analysts have issued twelve-month price targets for Synlogic's shares. Their SYBX share price targets range from $75.00 to $90.00. On average, they anticipate the company's share price to reach $82.50 in the next year. This suggests a possible upside of 3,351.9% from the stock's current price. Dec 1, 2023 · Based on short-term price targets offered by three analysts, the average price target for Synlogic, Inc. comes to $21.67. The forecasts range from a low of $6.00 to a high of $35.00. The average ... Chg %. Market Cap. Molecular Templates Inc. 4.65%. $33.48M. SYBX | Complete Synlogic Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full …What are the best stocks to buy? Learn how you can make that decision for yourself at InvestorPlace. With the help of experienced financial advisors, InvestorPlace can give you the info you need to form an effective investment strategy. So ...Third Quarter 202 1 Financial Results. As of September 30, 2021, Synlogic had cash, cash equivalents, and short-term investments of $150 .1 million. For the three months ended September 30, 2021 ...Founded Date 2014. Founders Alison Silva, Ankit Mahadevia, Dean Falb, Jim Collins, Timothy K. Lu. Operating Status Closed. Last Funding Type Post-IPO Equity. Legal Name Synlogic, Inc. Stock Symbol NASDAQ:SYBX. Company Type For Profit. Contact Email [email protected]. Phone Number (617)401-9975.Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.Nov 30, 2023 · Grading Synlogic Inc Stock. Before you choose to buy, sell or hold Synlogic Inc stock, you’ll want to analyze how it has been graded. Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, making sense of financial ratios, reading income statements and analyzing recent stock movement. SYBX Stock Performance Soars with 1,939.98% Increase: Analysts Predict Strong Growth for Synlogic Inc. SYBX stock had a significant performance on September 27, 2023. The 12-month price forecasts from three analysts for Synlogic Inc had a median target of $5.00, with a high estimate of $6.00 and a low estimate of $4.00.Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 19.23% and 80.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.Upon closing, Synlogic security holders are expected to own approximately 83.18% of the outstanding shares of MIRN common stock on a fully- diluted basis and security holders of MIRN as of immediately prior to the merger are expected to own approximately 16.82% of the outstanding shares of MIRN common stock.SYBX Stock Performance Soars with 1,939.98% Increase: Analysts Predict Strong Growth for Synlogic Inc. SYBX stock had a significant performance on September 27, 2023. The 12-month price forecasts from three analysts for Synlogic Inc had a median target of $5.00, with a high estimate of $6.00 and a low estimate of $4.00.Instagram:https://instagram. c3.ai share priceare 1979 silver dollars worth anythingbest futures brokers for day tradingday trade cash account About Synlogic. Synlogic ™ is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, Synlogic designs Synthetic Biotic medicines that target validated underlying biology to treat disease in new ways. mobile futures tradingbanks for the wealthy May 9, 2023 · About Synlogic Synlogic is the leading company advancing therapeutics based on synthetic biology. Synlogic’s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the first half of 2023, and additional novel drug candidates designed to treat ... is beagle legit 401k Based on short-term price targets offered by three analysts, the average price target for Synlogic, Inc. comes to $21.67. The forecasts range from a low of $6.00 to a high of $35.00. The average ...Top Public Companies. #5. Codexis. Revenue: $69.056 million in 2020; $18.032 million in Q1 2021. Codexis on June 17 raised its 2021 investor guidance after receiving a binding purchase order from ...